DOCSLIB.ORG

Dalbavancin • Oritavancin • Tedizolid • Ceftolozane/Tazobactam • Ceftazidime/Avibactam • Fecal Transplant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dalbavancin • Oritavancin • Tedizolid • Ceftolozane/Tazobactam • Ceftazidime/Avibactam • Fecal Transplant What’s New in Infectious Diseases? Bruce L. Gilliam, M.D. Institute of Human Virology University of Maryland School of Medicine Baltimore, MD Topics New Antibacterial Therapeutics Emerging Pathogens HIV Hepatitis C Disclosures Research Studies Pfizer – Staph aureus Vaccine Trial TaiMed Biologics - Ibaluzimab Advisory Board Viiv Healthcare New Antibacterial Therapeutics • Dalbavancin • Oritavancin • Tedizolid • Ceftolozane/tazobactam • Ceftazidime/avibactam • Fecal Transplant Incidence of Staph aureus hospitalizations in U.S.A., 2001–2009 BMC Infect Dis 2014, 14:296 Dalbavancin (Dalvance) • Derived from Teicoplanin • ½ life – Effective: 8.5 days – Terminal: 346 hrs (14 days) • Bactericidal • Similar spectrum to Vancomycin, active against: – Staphylococci • MSSA, MRSA, CoNS – Streptococci • resistant pneumococci • anaerobic strep – Enterococci • VRE with van B, C but not A – Corynebacterium Dalbavancin Once Weekly Non- Inferior to Vanco/Linezolid N Engl J Med 2014;370:2169-79. Single-Dose (1.5 g) Non-Inferior to Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection 100 90 80 70 60 50 Single Dose 40 Once Weekly 30 20 10 0 Overall Clinical Success Rate Success Rate Success Rate Response Day 14 Day 28 Day 14 MRSA Clin Infect Dis. 2015 Nov 26. pii: civ982. [Epub ahead of print] VA Experience with Dalbavancin • Background – Levels in bone > MIC for 14 days • 8 patients treated for osteomyelitis with IV Dalbavancin – Former IV drug users not eligible for home IV or unwilling to do home IV • Treated for up to 8 weeks • No adverse events • All with resolution of osteomyelitis • Cost savings vs. placement in facility Oritavancin (Orbactiv) • Derived from Vancomycin • ½ life – Terminal 245-393 hrs (10-16 days) • Bactericidal • Similar spectrum to Vancomycin, active against: – Staphylococci • MSSA, MRSA, CoNS – Streptococci • resistant pneumococci • anaerobic strep – Enterococci • VRE with van A, B, C – Corynebacterium Single Dose Oritavancin vs. Vancomycin in Acute Bacterial Skin Infections N Engl J Med 2014;370:2180-90. Should I use Dalbavancin or Oritavancin Dalbavancin Oritavancin • Short infusion: 30 min • Active against van A • Active against catheter enterococci related BSI • Few drug-drug • Long infusion: 3 hrs interactions – Infusion reaction if shorter • pK data in bone, tissue • Drug-drug interactions – 31% increase warfarin • Can prolong PTT and CT – No heparin within 48 hrs Tedizolid (Sivextro) • Oxazolidinone antibiotic • Prodrug • pK – ½ life 12 hrs – Once daily – >90% oral bioavailable • Bacteriostatic – Cidal in animal models • Not expected to have MAOI interactions • Microbiology – Staphylococci • MSSA, MRSA, CoNS – Streptococci • resistant pneumococci • anaerobic strep – Enterococci – Corynebacterium – Atypical mycobacteria Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections 100 90 80 70 60 50 Tedizolid 40 Linezolid 30 20 10 0 Early Response Sustained Response Investigator Treatment Success JAMA. 2013;309(6):559-569 Should I use Tedizolid or Linezolid Tedizolid Linezolid • Once daily • Now generic so lower • 6 days for ABSSSI cost • Potentially • Twice daily – Less MAOI interaction • 10 days for ABSSSI – Less hematologic effects • Interaction with MAOI • May be active against some linezolid resistant • Hematologic effects strains • Possible accumulation of • No dose adjustment in metabolites in renal hepatic or renal failure Numbers of carbapenemase-producing Enterobacteriaceae referred to the UK national reference laboratory – 2003- 2009 Lancet Infect Dis 2010; 10: 597–602 New Agents to Treat GNRs Ceftolozane Ceftazidime Tazobactam Avibactam Drugs. 2013 Feb;73(2):159-77. Pharmacotherapy. 2015 Aug;35(8):755-70. Pharmacotherapy. 2015 Jul;35(7):701-15. Ceftolozane/Tazobactam(Zerbaxa) • 1.5g (1g Ceftolozane 0.5g Tazobactam) every 8 hours – Needs renal adjustment • FDA approved for – Complicated urinary tract infections – Complicated intra-abdominal infections • Broad spectrum gram negative activity including – Pseudomonas aeruginosa (including MDR strains) – Some extended-spectrum beta-lactamases (ESBL) from the TEM-1 & 2, SHV, CTX-M and OXA groups – NOT active against organisms that produce serine carbapenemases (eg., KPCs) and metallo-beta lactamases • Other activity includes the Streptococcus milleri group (S. anginosus, S. constellatus, S. intermedius) and Bacteroides fragilis Ceftazidime/Avibactam (Avycaz) • 2.5 gm (2 gm ceftazidime, 0.5 gm avibactam) over 2 hours every 8 hours – Renal dose adjustments required • FDA approved for – Complicated urinary tract infections – Complicated intra-abdominal infections • Avibactam is a potent inhibitor of class A, class C and some class D beta-lactamases • Broad spectrum gram negative activity including Enterobacteriaceae including ESBLs (TEM, SHV, CTX- M) and KPC producers, and Pseudomonas – Minimal anaerobe coverage, high MICs for B. fragilis • Note - avibactam does not restore the activity of ceftazidime against P. aeruginosa as reliably as it does Enterobacteriaceae (likely due to other mechanisms of resistance such as porin alterations, efflux pumps, metallo-β-lactamases or OXA β-lactamases) When to use the GNR antibiotics • Ceftolozane/tazobactam • Ceftazidime/avibactam – FDA approved – FDA approved • UTI • UTI • cIAI • cIAI – Being studied in VABP – Being studied in VABP – Renal adjustment – Renal adjustment – Use – Use • MDR Pseudomonas • MDR Pseudomonas • Some ESBLs • ESBLs • Not active against KPC • Active against KPC – Cost $$$ – Cost $$$$$ • Need to check susceptibilities for use Incidence of Nosocomial Clostridium difficile Infection N Engl J Med 2015;372:1539-48. Antibiotic Classes and Their Association with Clostridium difficile infection • Careful use of antibiotics can make a difference – antimicrobial stewardship N Engl J Med 2015;372:1539-48 Treatment of Clostridium difficile infection N Engl J Med 2015;372:1539-48 Rates of Cure and Changes to the Microbiota after Fecal Microbial Transplantation for Recurrent Clostridium difficile Infection. N Engl J Med 2015;372:1539-48 Emerging Pathogens • Ebola • Zika • Chikungunya • Borrelia miyamotoi Ebola Virus • Filovirus • Clinical – Fever, severe headache, muscle pain, weakenss, fatigue, diarrhea, vomiting, abd pain, unexplained hemorrhage (bleeding or bruising) – Incubation: 8-10 days(range 2-21 days) – Mortality rate: 25-90% Ebola What Did We Learn • Ebola virus disease survivors frequently reported anorexia and arthralgia • Persistence – Semen – detected 284 days after symptoms – Aqueous humour – detected 9 weeks after recovery – Vaginal fluids, sweat, urine, and breast milk – CNS symptoms 9 months after recovery • Can be sexually transmitted • Transfusion of plasma from convalescent donors did not improve survival – Neutralizing Ab levels not checked • Patients receiving Artesunate-amodiaquine had a 31% lower risk of death than those receiving artemether-lumefantrine N Engl J Med. 2016 Jan 7;374(1):33-42 N Engl J Med. 2015 Jun 18;372(25):2423-7. BMJ Open. 2016 Jan 7;6(1):e008859 N Engl J Med. 2016 Jan 7;374(1):23-32 Int J Infect Dis 2016; 43; 58-61 N Engl J Med. 2015 Oct 14 N Engl J Med. 2015 Dec 17;373(25):2448-54 Ebola What Did We Learn • Multilevel, interprofessional collaboration to isolate HID cases and reduce disease transmission will be crucial to contain future outbreaks1 • Potential therapies – Virus-neutralizing antibody cocktail (ZMab) – Vesicular stomatitis virus-vectored Ebola glycoprotein vaccine (rVSV/ZEBOV-GP) – T-705 (favipiravir) - nucleotide analog – BCX4430 – nucleoside analogue 1. Infect Control Hosp Epidemiol. 2015 Dec 8:1-6. [Epub ahead of print] Zika Virus • Arbovirus • First isolated in Zika Forest Uganda 1947 • Transmitted by Aedes mosquito • Incubation: 3-12 days • Symptoms: mild fever, arthralgia (small joints of hands and feet), myalgia, HA, asthenia, abdominal pain, edema, lymphadenopathy, retro-orbital pain, conjunctivitis, and cutaneous maculopapular rash • Largely limited to Africa and Asia until 2015 when spread to Brazil, Columbia, Venezuela, Mexico • Now cases in Puerto Rico, Texas, Hawaii Distribution of Zika Virus http://www.cdc.gov/zika/geo/index.html Zika Virus in Travelers returning from the Cook Islands • Conjunctivitis and Rash Clin Infect Dis. 2015; 61 (9): 1485-1486 Zika vs. Dengue • Conjunctivitis – 17/31 [55%] of ZIKA patients vs 14/148 [9%] DENGUE patients • Absence of thrombocytopenia • Rash – more common in ZIKA – 28/31 [90%] ZIKA patients [5] vs 44/148 [30%] DENGUE patients Clin Infect Dis. 2015; 61 (9): 1485-1486 Zika Virus Why is it Important • Largely limited to Africa and Asia until 2015 when spread to Brazil, Columbia, Venezuela, Mexico • Now in Puerto Rico, Texas, Hawaii – Texas case in traveler from El Salvador – Local transmission reported in Samoa, Puerto Rico, Mexico, Carribbean, Central and South America • Linked to – Microcephaly in pregnant women with infection • 1200-4000 cases in Brazil(up from 150-200) coincident with outbreak • Brazilian government recommending that mothers delay conception – Guillain-Barre syndrome • What can you do – Mosquito control/avoidance – No treatment • Test Pregnant women for Zika in consult with health dept if – history of travel to an area with Zika virus transmission – and 2+ symptoms consistent with Zika virus disease during or within 2 weeks of travel • acute onset of fever, maculopapular rash, arthralgia, or conjunctivitis – or have US findings of fetal microcephaly or intracranial calcifications • All pregnant women consider postponing
Load more

Recommended publications
  • The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin Lisa Pasierb
    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 2005 The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin Lisa Pasierb Follow this and additional works at: https://dsc.duq.edu/etd Recommended Citation Pasierb, L. (2005). The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1021 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin A Dissertation presented to the Bayer School of Natural and Environmental Sciences of Duquesne University As partial fulfillment of the requirements for the degree of Doctor of Philosophy By Lisa Pasierb August 26, 2005 Dr. David Seybert, thesis director Dr. David W. Wright, advisor In memory of Anna Pasierb April 24, 1924 – May 31, 2005 ii Acknowledgements First and foremost, I would like to express my sincerest gratitude to my advisor, Dr. David W. Wright. His exuberating energy and conviction attracted me to his research group, while his unwavering faith in me taught me more than he could ever know. Secondly, of course, I would like to extend my appreciation to Glenn Spreitzer and James Ziegler, the other two original members of the Wright group, whom initially tried to exert male dominance, but eventually became very faithful friends and colleagues. Finally, to all the other members of the Wright group over the years, thanks for all of your help, suggestions, and camaraderie.
    [Show full text]
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • Jos Journal 2
    POST-OPERATIVE AUDIT OF G6PD-DEFICIENT MALE CHILDREN WITH OBSTRUCTIVE ADENOTONSILLAR ENLARGEMENT AT UNIVERSITY COLLEGE HOSPITAL, IBADAN, NIGERIA. John EN1, Totyen EL1, Jacob N2, Nwaorgu OGB1 1 .Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria 2. Department of paediatrics, University College Hospital, Ibadan, Nigeria All correspondences and request for reprint to Dr John EN, Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria Email: [email protected] Telephone: +2348036240109 Abstract Background: G6PD deficiency ranks among the commonest hereditary enzyme deficiency worldwide and notable as a predisposing condition to haemolyticcrises. The fear of possible untoward effects is often expressed by parents of G6PD deficient male children scheduled for surgery after obtaining an informed and understood consent. The parental perception of obstructive adenotonsillar enlargement in this condition was also appraised. Methods: A retrospective chart review of all G6PD deficient male children between ages 1 to 7years who had adenotonsillectomy over a 3year period at University college Hospital, Ibadan, Nigeria. Results: The patients comprised of 22 G6PD deficient male children diagnosed shortly after birth upon development of neonatal jaundice. Fifteen(68.2%) and 6(27.3%) of the patients subsequently developed episodes of drug- induced haemolysis and non-haemolytic drug reactions prior to undergoing adenotonsillectomy by the otolaryngologists. None of the patients was observed to develop haemolytic crises up to 2weeks post-adenotonsillectomy. From the parental perception and responses in the follow-up period,all 22(100%) patient had resolution of noisy breathing, 20(91%) had improvement of snoring and apnoeic spells. Only 15 (68%) were reported to stop mouth-breathing.
    [Show full text]
  • Annex 4: Drug Dosages for Children (Formulary)
    Medicines Dosage Form Dose according to body weight (calculate if weight is below or over) 3-6 kg 6-10 kg 10-15 kg 15-20 kg 20-29 kg albendazole 200 mg (half tablet) 12-24 months chewable tablet, 400mg 400 mg (one tablet) over 24 months amodiaquine 10 mg base/kg/3 days (total dose 30 mg base/kg) tablet, 200mg - - 1 1 1 amoxicillin 15 mg/kg/dose for 7 days tablet/capsule 250 mg ¼ ½ ¾ 1 1½ oral suspension, 125mg/5ml 2.5 ml 5 ml 7.5 ml 10 ml - non-severe pneumonia: 25 mg/kg 2 times per day for 3 days tablet/capsule 250 mg ½ 1 1½ 2 2½ oral suspension, 125mg/5ml 5 ml 10 ml 15 ml - - ampicillin IM 50 mg/kg/6 hours Vial of 500 mg mixed with 2.1 ml 1 ml 2 ml 3 ml 5 ml 6 ml sterile water to give 500 mg/2.5 ml artemether IM 3.2 mg/kg once on day 1 injection, 40mg/ml in 1ml ampoule then injection, 80mg/ml in 1ml ampoule see Chapter 5, management of the child with malaria IM 1.6 mg/kg daily until oral therapy is possible, total therapy one week artemether + fixed dose treatment (20+120 mg) twice daily for 3 days tablet 10+120 mg see Chapter 5, management of the child with malaria lumefantrine artesunate severe malaria: IV or IM 2.4 mg/kg over 3 minutes at 0, 12 and 24 vial of 60 mg in 0.6 ml with 3.4 ml hours on day 1.
    [Show full text]
  • Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics
    1521-009X/44/8/1229–1245$25.00 http://dx.doi.org/10.1124/dmd.116.071753 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1229–1245, August 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Special Section on Emerging Novel Enzyme Pathways in Drug Metabolism—Commentary Cytochrome P450 and Non–Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics Robert S. Foti and Deepak K. Dalvie Pharmacokinetics and Drug Metabolism, Amgen, Cambridge, Massachusetts (R.S.F.); and Pharmacokinetics, Dynamics, and Metabolism, Pfizer, La Jolla, California (D.K.D.) Downloaded from Received May 24, 2016; accepted June 10, 2016 ABSTRACT The drug-metabolizing enzymes that contribute to the metabolism this end, this Special Section on Emerging Novel Enzyme Pathways or bioactivation of a drug play a crucial role in defining the in Drug Metabolism will highlight a number of advancements that dmd.aspetjournals.org absorption, distribution, metabolism, and excretion properties of have recently been reported. The included articles support the that drug. Although the overall effect of the cytochrome P450 (P450) important role of non-P450 enzymes in the clearance pathways of family of drug-metabolizing enzymes in this capacity cannot be U.S. Food and Drug Administration–approved drugs over the past understated, advancements in the field of non-P450–mediated me- 10 years. Specific examples will detail recent reports of aldehyde tabolism have garnered increasing attention in recent years. This is oxidase, flavin-containing monooxygenase, and other non-P450 perhaps a direct result of our ability to systematically avoid P450 pathways that contribute to the metabolic, pharmacokinetic, or liabilities by introducing chemical moieties that are not susceptible pharmacodynamic properties of xenobiotic compounds.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Efficacy and Safety of Methylene Blue in the Treatment of Malaria: a Systematic Review G
    Lu et al. BMC Medicine (2018) 16:59 https://doi.org/10.1186/s12916-018-1045-3 RESEARCH ARTICLE Open Access Efficacy and safety of methylene blue in the treatment of malaria: a systematic review G. Lu1,2, M. Nagbanshi2, N. Goldau2, M. Mendes Jorge2, P. Meissner3, A. Jahn2, F. P. Mockenhaupt4 and O. Müller2* Abstract Background: Methylene blue (MB) was the first synthetic antimalarial to be discovered and was used during the late 19th and early 20th centuries against all types of malaria. MB has been shown to be effective in inhibiting Plasmodium falciparum in culture, in the mouse model and in rhesus monkeys. MB was also shown to have a potent ex vivo activity against drug-resistant isolates of P. falciparum and P. vivax. In preclinical studies, MB acted synergistically with artemisinin derivates and demonstrated a strong effect on gametocyte reduction in P. falciparum. MB has, thus, been considered a potentially useful partner drug for artemisinin-based combination therapy (ACT), particularly when elimination is the final goal. The aim of this study was to review the scientific literature published until early 2017 to summarise existing knowledge on the efficacy and safety of MB in the treatment of malaria. Methods: This systematic review followed PRISMA guidelines. Studies reporting on the efficacy and safety of MB were systematically searched for in relevant electronic databases according to a pre-designed search strategy. The search (without language restrictions) was limited to studies of humans published until February 2017. Results: Out of 474 studies retrieved, a total of 22 articles reporting on 21 studies were eligible for analysis.
    [Show full text]
  • Application for Inclusion of Artesunate/Amodiaquine Fixed Dose Combination Tablets in the Who Model Lists of Essential Medicines
    SANOFI-AVENTIS artesunate/amodiaquine Application for inclusion in the WHO Model Lists of essential medicines June 2009- updated Sept. 2010 APPLICATION FOR INCLUSION OF ARTESUNATE/AMODIAQUINE FIXED DOSE COMBINATION TABLETS IN THE WHO MODEL LISTS OF ESSENTIAL MEDICINES Artesunate / Amodiaquine, Fixed dose combination 1/57 25 mg/ 67.5 mg, 50 mg/ 135 mg and 100 mg/270 mg SANOFI-AVENTIS artesunate/amodiaquine Application for inclusion in the WHO Model Lists of essential medicines June 2009- updated Sept. 2010 TABLE OF CONTENT 1. Summary statement of the proposal for inclusion p.4 2. Name of the focal point in WHO submitting or supporting the p.9 Application 3. Name of the organisation(s) consulted and/or supporting the p.10 Application 4. International Non-proprietary Name (INN, generic name) of p.10 the medicine 5. Dosage form or strength proposed for inclusion p.10 5.1. Chemical characteristics p.10 5.2. The formulation proposed for inclusion p.11 5.3. Stability of the formulation p.14 6. International availability – sources, if possible manufacturers p.14 6.1. Sources and manufacturers p.14 6.2. History of the product p.15 6.3. International availability and production capacity p.16 7. Whether listing is requested as an individual medicine or as an p.17 example of a group 8. Information supporting the public health relevance p.18 (epidemiological information on disease burden, assessment of current use, target population) 9. Treatment details p.22 9.1. Method of administration p.22 9.2. Dosage p.22 9.3. Duration p.22 9.4.
    [Show full text]
  • Methylene Blue for the Treatment of Health Conditions: a Scoping Review
    Vol.64: e21200266, 2021 https://doi.org/10.1590/1678-4324-20212002660266 ISSN 1678-4324 Online Edition Review - Human and Animal Health Methylene Blue for the Treatment of Health Conditions: a Scoping Review Jessica Galvan1* Luciane Patrícia Andreani Cabral2 https://orcid.org/0000-0002-3261-8521 https://orcid.org/0000-0001-9424-7431 Mariana Xavier Borsoi1 Marcos Cezar Pomini3 https://orcid.org/0000-0003-4940-8149 https://orcid.org/0000-0001-8129-7165 Luciana Julek1 Fabiana Bucholdz Teixeira Alves2 https://orcid.org/0000-0001-6898-6839 https://orcid.org/0000-0001-9955-1811 Danielle Bordin2 https://orcid.org/0000-0001-7861-0384 1Campos Gerais Regional University Hospital (HURCG), State University of Ponta Grossa (UEPG), Department of Nursing and Health Public, Ponta Grossa, Paraná, Brazil; 2State University of Ponta Grossa (UEPG), Ponta Grossa, Paraná, Brazil. 3Piracicaba Dental School, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil. Editor-in-Chief: Paulo Vitor Farago Associate Editor: Paulo Vitor Farago Received: 2020.05.03; Accepted: 2020.09.10. *Correspondence: [email protected]; Tel.: +55-44-99980-7290 (J.G.). HIGHLIGHTS This scoping review summarizes the findings of clinical trials using methylene blue (MB) for the treatment of various health conditions. This research method allowed mapping main findings, clarifying research topics, and identifying gaps in the literature. Abstract: studies evaluating effective drugs for health conditions are of crucial importance for public health. Methylene blue (MB) is an accessible synthetic drug that presents low toxicity and has been used in several health areas due to its effectiveness. Objective: this scoping review aims to provide a comprehensive overview of relevant research regarding the use of MB for the treatment of health conditions.
    [Show full text]
  • Pharmaceutical Impurities and Degradation Products: Uses And
    Journal of Pharmaceutical and Biomedical Analysis 101 (2014) 102–122 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis j ournal homepage: www.elsevier.com/locate/jpba Review Pharmaceutical impurities and degradation products: Uses and applications of NMR techniques ∗ Rubén M. Maggio, Natalia L. Calvo, Silvana E. Vignaduzzo, Teodoro S. Kaufman Instituto de Química Rosario (IQUIR, CONICET–UNR) and Área Análisis de Medicamentos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, Rosario S2002LRK, Argentina a r a t b i c s t l e i n f o r a c t Article history: Current standards and regulations demand the pharmaceutical industry not only to produce highly pure Received 25 February 2014 drug substances, but to achieve a thorough understanding of the impurities accompanying their manufac- Received in revised form 11 April 2014 tured drug substances and products. These challenges have become important goals of process chemistry Accepted 12 April 2014 and have steadily stimulated the search of impurities after accelerated or forced degradation procedures. Available online 24 April 2014 As a result, impurity profiling is one of the most attractive, active and relevant fields of modern pharmaceutical analysis. This activity includes the identification, structural elucidation and quantitative Keywords: determination of impurities and degradation products in bulk drugs and their pharmaceutical formula- NMR spectroscopy tions. Pharmaceutical impurities LC–NMR Nuclear magnetic resonance (NMR) spectroscopy has evolved into an irreplaceable approach for phar- Structural elucidation maceutical quality assessment, currently playing a critical role in unequivocal structure identification Qualitative and quantitative analysis as well as structural confirmation (qualitative detection), enabling the understanding of the underlying mechanisms of the formation of process and/or degradation impurities.
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Medical Review(S) Review of Request for Priority Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22-268 MEDICAL REVIEW(S) REVIEW OF REQUEST FOR PRIORITY REVIEW To: Edward Cox, MD, MPH Director, Office of Antimicrobial Products Through: Renata Albrecht, M.D Director, DSPTP, OAP From: Joette M. Meyer, Pharm.D. Acting Medical Team Leader, DSPTP, OAP NDA: 22-268 Submission Date: 6/27/08 Date Review Completed 7/25/08 Product: Coartem (artemether/lumefantrine) Sponsor: Novartis Pharmaceuticals Corporation East Hanover, NJ Proposed Indication: Treatment of malaria in patients of 5kg body weight and above with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum Proposed Dosing Regimen: A standard 3-day treatment schedule with a total of 6 doses is recommended and dosed based on bodyweight: 5 kg to < 15 kg: One tablet as an initial dose, 1 tablet again after 8 hours and then 1 tablet twice daily (morning and evening) for the following two days 15 kg to < 25 kg bodyweight: Two tablets as an initial dose, 2 tablets again after 8 hours and then 2 tablets twice daily (morning and evening) for the following two days 25 kg to < 35 kg bodyweight: Three tablets as an initial dose, 3 tablets again after 8 hours and then 3 tablets twice daily (morning and evening) for the following two days 35 kg bodyweight and above: Four tablets as a single initial dose, 4 tablets again after 8 hours and then 4 tablets twice daily (morning and evening) for the following two days Abbreviations A artemether ACT artemisinin-based combination therapy AL artemether-lumefantrine
    [Show full text]